PRFX PainReform Ltd.

Latest News

1. 17 May 2022 PainReform Provides Business Update for the First Quarter of 2022

   TEL AVIV, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, yesterday provided a business update for the first quarter ended March 31, 2022.
   

   Ilan Hadar, Chief Executive Officer of Pain Reform, stated, "We are continuing our steady progress towards commencing the Phase 3 clinical trial of PRF-110 in bunionectomy expected in the second half of 2022. Having been approved for the 505(b)(2) pathway by the FDA, we expect this to be a rapid and cost-efficient trial.   Importantly, the manufacturing tech transfer to our selected CMO, whom we engaged for manufacturing our clinical batches…

   View Full Article
2. 12 April 2022 PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

   TEL AVIV, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will present at the Noble Capital Markets' Eighteenth Annual Investor Conference being held on April 20-21, 2022 at the Hard Rock Hotel & Casino in Hollywood, Florida.
   

   Mr. Hadar will present on Wednesday, April 20^th at 12:00 pm Eastern Time, in the Seminole Ballroom C. Investors interested in meeting with management can meet at the breakout session on Wednesday, April 20^th at 4:00 pm Eastern Time at Table 9.

   A high-definition, video webcast of the presentation will be available the…

   View Full Article
3. 21 March 2022 PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

   TEL AVIV, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.
   

   The conference will feature roundtable discussions, fireside chats, and multiple company presentations, including a pre-recorded corporate update from Ilan Hadar, CEO of PainReform. Those who wish to attend must first sign up to become an M-Vest member.

   Sign up here to access the presentation.

   About PainReform

   PainReform is a clinical-stage specialty…

   View Full Article
4. 17 March 2022 PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

   TEL AVIV, Israel, March 17, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2021.
   

   Ilan Hadar, Chief Executive Officer, stated, "We remain on track to commence our Phase 3 clinical trial of PRF-110 in bunionectomy in the second half of 2022. Specifically, we are advancing the manufacturing of PRF-110 clinical batches with our partner Pharmaceutics International, Inc. (PII), a U.S.-based contract manufacturing organization (CMO). After completion of the first trial, we plan to initiate the Phase 3 hernia repair clinical trial based…

   View Full Article
5. 14 December 2021 PainReform CEO to Participate in the Benzinga All Access Event on December 16th

   TEL AVIV, Israel, Dec. 14, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be participating in the Benzinga All Access event taking place on December 16, 2021.

   Mr. Hadar is scheduled to appear on December 16, 2021 at 10:00 A.M. Eastern Time. The event will consist of an interview hosted by Spencer Israel, Executive Producer of Benzinga TV.

   The event will be broadcast live and can be viewed here. An archived recording of the presentation will be available on the investor relations section of PainReform's website at painreform.com/ir-events/…

   View Full Article